The Priority Review

Tag

FDA

70 stories ยท page 5 of 6

Stories

  1. Regulation

    FDA actions, week of September 28, 2026: 1 approval, 1 rule, 3 notices

    The FDA published 5 actions in the week of September 28 to October 4, 2026: 1 approval announcement, 1 final rule in the Federal Register and 3 notices in the Federal Register.

  2. Regulation

    FDA actions, week of October 5, 2026: 3 approvals, 5 rules, 7 notices, 1 announcement

    The FDA published 16 actions in the week of October 5 to 11, 2026: 3 approval announcements, 5 final rules in the Federal Register, 7 notices in the Federal Register and 1 press announcement.

  3. Regulation

    FDA corrects withdrawal notice of 16 ANDAs

    The FDA issued a correction to a June 3, 2026 notice that announced the withdrawal of approval of 16 abbreviated new drug applications, effective July 6, 2026. The correction removes entries for ANDA 207366, ANDA 212957, and ANDA 218638, noting that Navinta LLC requested the approvals not be withdrawn, so those approvals remain in effect.

  4. Regulation

    FDA withdraws approval of 37 ANDAs

    The agency is withdrawing approval of 37 abbreviated new drug applications from multiple applicants. The applicants notified the FDA that the drug products were no longer marketed and requested the approvals be withdrawn.

  5. Regulation

    FDA issues priority review voucher for ZANVASTRO

    FDA approved ZANVASTRO on September 3, 2026. FDA issued a priority review voucher to the sponsor, Ionis Pharmaceuticals, Inc., after determining the product meets the criteria under the FD&C Act.

  6. Regulation

    FDA classifies hematopoietic cell enrichment kit as class II device

    The order designates the kit as a class II device with special controls. The special controls will be part of the codified language for classification of the hematopoietic cell enrichment kit.

  7. Regulation

    FDA classifies infant pulse rate and oxygen saturation monitor as class II

    The order assigns the device to class II, adding special controls to the codified language. The action is expected to enhance patients' access to beneficial innovative devices by reducing regulatory burdens.

  8. Regulation

    FDA requests public comments on ibogaine trial design

    FDA is opening a docket to receive comments on design elements for early-phase trials of ibogaine drug products, with a deadline of November 20, 2026. The request follows guidance issued July 14, 2026 and seeks input on dose selection, safety monitoring, eligibility criteria and other protocol elements.

  9. Regulation

    FDA issues priority review voucher for FAYUVI (rebisufligene etisparvovec-hopf)

    The FDA announced that it has awarded a priority review voucher to the sponsor of FAYUVI, a gene therapy approved on September 17, 2026. The voucher is granted to Ultragenyx Pharmaceutical Inc. for this rare pediatric disease product that meets the criteria under the FD&C Act.

  10. Regulation

    FDA determines pralidoxime chloride AUTOINJECTOR not withdrawn for safety or effectiveness

    FDA has determined that pralidoxime chloride AUTOINJECTOR solution, 600 mg/2 mL (300 mg/mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination allows FDA to approve abbreviated new drug applications for the product if other requirements are met.

  11. Regulation

    FDA classifies focused ultrasound system as class II

    The Food and Drug Administration issued a final order classifying the focused ultrasound system for non-thermal, mechanical tissue ablation into class II with special controls, effective October 6, 2026. The order codifies the classification in 21 CFR 878.4405 and identifies the special controls that will provide reasonable assurance of safety and effectiveness.

  12. Regulation

    FDA finalizes class II status for hyperoxia monitoring device adjunct to pulse oximetry

    The FDA issued a final order on October 6, 2026, classifying the hyperoxia monitoring device adjunct to pulse oximetry into class II with special controls. The order, effective October 6, 2026, codifies the classification that was first applied on October 12, 2023.